Recent clinical trials and animal studies indicate that resistant starches may be beneficial therapeutic tools for the management of metabolic diseases. The purpose of this review is to summarize these findings and discuss the established and proposed mechanisms by which resistant starches exert their benefits. We also examine open questions regarding how resistant starches improve metabolism and propose future research directions for the field.
INTRODUCTION
Obesity is rapidly becoming a major global health challenge. From 1980 to 2013, the proportion of overweight adults increased worldwide from 29 to 37% [1] . Abdominal adiposity is the primary risk factor for development of metabolic diseases such as type 2 diabetes (T2D) and cardiovascular disease [2, 3] .
Traditional approaches to treating obesity and its related diseases have emphasized appropriate dietary choices and increased physical activity. One of the nutritional interventions proposed to counteract metabolic diseases is dietary supplementation with resistant starches. Resistant starches include all starch and starch degradation products that escape digestion in the small intestine of healthy individuals because they are physically inaccessible, either within the food matrix (resistant starch type 1) or within starch granules (resistant starch type 2) or because they are present as retrograded starch (resistant starch type 3), which is produced during food manufacture and preparation. In addition, starch can also be chemically modified (resistant starch type 4) to make it resistant to enzymatic digestion [4 & ].
Resistant starches offer many practical advantages for use in the management of obesityassociated pathologies when compared with other fibers. Resistant starches can easily replace regular starch in baked goods and, by being nondigestible, can reduce both the caloric density and glycemic index of food products. However, resistant starches exert physiological effects that go beyond resistance to digestibility, including modulation of satiety ,6 && ,7]. In this review, we provide an overview of recent studies that investigated the potential of various resistant starch types to manage metabolic disorders. We then discuss the established and proposed mechanisms by which resistant starches exert metabolic benefits. Finally, we examine open questions regarding how resistant starches improve metabolism and propose future research directions for the field.
RESISTANT STARCHES TO COMBAT METABOLIC DISEASES
Resistant starches were first characterized in 1982 and then rapidly studied for their ability to improve colonic health [8] . Since then, considerable effort has also been devoted to investigating the metabolic effects of resistant starches using both human clinical trials and animal models [5 & ,6 && ]. In particular, several recent studies have strengthened the concept that resistant starches confer metabolic benefits.
Modulation of insulin resistance and glucose homeostasis
Improved insulin resistance and glucose homeostasis are arguably the best-characterized metabolic benefits associated with resistant starch consumption [6 && ,9] . Although these effects are well documented in healthy individuals and those with metabolic syndrome, information regarding its impact on populations with established metabolic disease is lacking.
In a recent clinical trial, Bodinham et al. [6 && ] addressed this issue by assessing the effects of resistant starch type 2 consumption on insulin sensitivity and glucose control in patients with T2D. Resistant starch type 2 improved postprandial glucose levels, but had no impact on hepatic or peripheral insulin sensitivity as assessed by the hyperinsulinemic clamp technique [6 && ]. It appears that resistant starches can improve insulin sensitivity in healthy and prediabetic individuals but not after T2D has been established.
Recent studies regarding resistant starch feeding and glucose control unfortunately show conflicting results. In particular, Zhou et al. [10] observed significant decreases in blood glucose levels compared with controls when resistant starch type 2 (8% w/w) was fed to streptozotocin-induced diabetic rats. This was in contrast to Harazaki et al. [11 & ] who reported that feeding resistant starch type 2 (55% w/w) significantly decreased fasting insulin levels and the index of insulin resistance but did not change glucose tolerance in an OLETF rat model of T2D.
There is clearly good evidence that resistant starches improve glucose metabolism beyond what would be expected from its reduced glycemic index, but to what extent established pathologies can be reversed is still unclear, and some studies do not show a beneficial effect on glycemic variables [12,13 & ]. Differences in resistant starch intake levels, resistant starch source, timeframe, and disease status, among other factors (such as gut microbiota variation), could explain these apparent discrepancies, as discussed later in this review. 
Alterations in body weight, body composition, and dyslipidemia

KEY POINTS
Recent clinical studies show that feeding resistant starches can have a positive effect on insulin sensitivity and dyslipidemia, with little to no impact on body composition.
Several pathways -gut microbiota-dependent and gut microbiota-independent -are likely involved in conferring the metabolic benefits associated with consuming resistant starches.
Despite promising findings, the exact role of the gut microbiota in mediating the metabolic benefits of resistant starches remains to be determined.
Gut microbiota variation among animal facilities, human populations, and even individuals, might contribute to inconsistencies observed regarding the effects of resistant starches.
Resistant starches encompass a wide variety of structures -this heterogeneity must be considered and could explain, at least in part, some apparent discrepancies among studies. significantly decreased their total serum cholesterol levels. These two clinical trials provide exciting evidence that resistant starch feeding positively influences dyslipidemia.
Also of interest, Nichenametla et al. [13 & ] found that only healthy persons consuming resistant starch type 4-enriched flour experienced significant (albeit it minor) effects on their waist circumference and percentage body fat; no such effects were observed for individuals with metabolic syndrome. This is in line with the aforementioned Bodinham et al. [6 && ] study in which T2D patients experienced no changes in body weight, fat mass, or body fat depots despite decreases in fasting free fatty acid levels. Dodevska et al.
[12] did report significant decreases in body weight and waist circumference, but the changes were minor. All told, these recent reports demonstrate that dietary supplementation with resistant starches has little to no impact on body composition in humans with metabolic disease.
MECHANISMS UNDERPINNING THE HEALTH EFFECTS OF RESISTANT STARCHES
The ways in which resistant starches exert their health effects are insufficiently understood, but recent research has provided new insight into potential mechanisms. It has long been recognized that resistant starches essentially function like fermentable fibers as well as bulking agents. To that end, we will examine the potential mechanisms by which resistant starches impact metabolic processes, including those that involve the gut microbiota and those that may not.
The gut microbiota, short-chain fatty acids, and beyond
The community of microbes inhabiting the intestinal tract (the gut microbiota) provides critical control over host energy metabolism, insulin sensitivity, and immune development and regulation [ ] showed that feeding resistant starch type 2 to mice (30% w/w) increased both the full cecum and cecal tissue weights (indicative of fermentation), increased cecal expression of PYY and proglucagon (the precursor of GLP-1), and decreased body fat. The antiobesity effect was dependent on GLP-1-receptor (GLP-1R) and PYY, as the resistant starch-mediated reduction in body fat was not observed in mice receiving a daily injection of a PYY receptor antagonist or in GLP-1R-deficient mice. Although this study did not address glucose homeostasis, future research should determine whether GLP-1 induction is a mechanism by which resistant starches improve glucose control.
Information regarding the impact of resistant starch type 2 on GLP-1 in human trials is inconsistent. Resistant starch-mediated improvements in insulin sensitivity have been observed without a concomitant impact on GLP-1 levels [5 & ]. In the Bodinham et al. [6 && ] study, feeding resistant starch type 2 to T2D patients for 12 weeks lowered fasting GLP-1 levels but increased GLP-1 postprandial excursion during a meal tolerance test. The latter result is in contrast with the previous observation that postprandial GLP-1 levels were significantly lower following acute resistant starch type 2 consumption [30] . Bodinham et al. also reported significant decreases in butyrate and propionate (with no change in acetate) levels in the serum of resistant starch type 2-fed T2D patients. Although a decreased serum level of these SCFA does not necessarily preclude their production in the intestine, it does, however, exclude these microbial metabolites as systemic drivers of any peripheral effects of resistant starch type 2 such as lipolysis.
Modulation of bile acids, innate immunity, and inflammatory mediators
By functioning like a fiber, and subsequently bulking and increasing digesta viscosity, resistant starches are also likely to exert some effects independently of their impact on the gut microbiota. One of these alternative mechanisms could involve bile acids. Indeed, various types of resistant starches have been shown to impact bile acid excretion [31] . Bile acids control glucose homeostasis and insulin resistance via binding of the nuclear farnesoid X receptor and the cell membrane receptor TGR5 [27] . Indeed, recent work has elegantly shown that macrophage-specific deletion of Tgr5 increased adipose tissue macrophage accumulation and aggravated insulin resistance in obese animals [28] . How resistant starches modulate bile acid profiles remains to be more deeply characterized, but two scenarios can be envisioned. On the one hand, resistant starches could influence the bile pool by modulating specific microbial taxa that chemically transform bile acids. On the other, resistant starches may impact the concentration and reabsorption of bile acids via direct binding, bulking, and increasing viscosity [31] (Fig. 1) .
The notion that resistant starches modulate the immune system and insulin resistance through modulation of the bile acid profile is an underexplored concept that deserves further attention. describing reduced insulinemia in resistant starch type 2-fed T2D rats was the first to report a potential link between resistant starches and regulation of immune cell populations. Specifically, feeding resistant starches was associated with decreased adipose tissue expression of CD11c, a marker expressed on antigen presenting cells and proinflammatory macrophages. This finding is of considerable interest, as deletion of CD11c expressing cells has previously been shown to normalize insulin sensitivity in obese, insulin-resistant animals [32] . Macrophages can also secrete a myriad of proinflammatory cytokines, including tumor necrosis factor alpha (TNF-a), interleukin-6 and interleukin-1 beta. Bodinham et al. reported a 60% decrease in plasma TNF-a levels following 12 weeks of resistant starch type 2 feeding. Over-expression of TNF-a has long been hypothesized to play a significant role in the pathophysiology of insulin resistance [33] . Regulation of innate immune cells and their inflammatory mediators via bile acids may be a potential mechanism by which resistant starches improve glucose homeostasis and insulin resistance, but additional studies are needed.
OPEN QUESTIONS AND FUTURE RESEARCH DIRECTIONS
Several challenges remain in regards to understanding how resistant starches improve metabolism. Here, we identify a few key questions for the field and discuss potential answers in light of the latest findings.
What is the exact role of the gut microbiota in the health effects of resistant starches?
Recent evidence implicates the gut microbiota in precipitating the numerous health effects attributed to resistant starches. Like other fibers, resistant starches are fermented by the gut microbiota to [24] . Resistant starches could also alter the bile acid profile via gut microbiota-dependent and independent pathways. Bile acids control glucose homeostasis via binding of the nuclear farnesoid X receptor (FXR) and the cell membrane receptor TGR5 [27] .
In particular, recent work has shown that macrophage-specific deletion of Tgr5 increased adipose tissue macrophage accumulation and aggravated insulin resistance in obese animals [28] . GLP-1: glucagon-like peptide 1; PYY: peptide YY, SCFA: short chain fatty acids.
SCFA -microbial metabolites whose physiological effects are increasingly recognized [24,25 & ]. In addition, resistant starches shift the intestinal microbiota composition by enhancing putatively health-promoting taxa. Human trials in healthy volunteers demonstrated that feeding resistant starch type 2 and resistant starch type 3 increased the abundance of Ruminococcus bromii and Eubacterium rectale, whereas resistant starch type 4 had a major bifidogenic effect [18, 34] . In addition, administration of resistant starch type 3 to pigs increased Faecalibacterium prausnitzii and reduced the abundance of Escherichia coli and Pseudomonas spp. [21] . Eubacterium rectale and Faecalibacterium prausnitzii are major butyrate producers with anti-inflammatory properties [35] , and bifidobacteria are generally considered health-promoting organisms, thus, resistant starch-induced shifts in microbiota composition, in addition to metabolic effects, might contribute to health outcomes.
Despite these promising findings, the exact role of the gut microbiota in mediating the effects of resistant starches has not been systematically studied. As we discussed above, several of the beneficial effects of resistant starches may occur without microbial contributions. Strong correlations between resistant starches feeding and taxa changes could result simply from host and microbiome responding independently to the diet. Comparing the effects of resistant starches in conventional and germ-free animals would constitute a tractable model to separate direct versus microbiota-mediated effects [36] . Recent work from our own laboratory has revealed that feeding resistant starch type 2 or resistant starch type 4 supplemented Western diets to both germ-free and conventionalized mice improved their index of insulin resistance, indicating microbiome-independent mechanisms do exist (LB Bindels, J Walter, and AE Ramer-Tait, unpublished data). As gnotobiotic mouse models and protocols for microbiota transplants become more widely available, this line of research not only has the potential to determine the causative role of the microbiome in the health effects of dietary fiber (which will be critical for determining which fibers qualify for a prebiotic designation [37 & ]), but it will also facilitate direct testing of cultured strains with specific characteristics to ultimately identify individual bacterial contributors and underlying mechanisms [36] .
What accounts for the discrepancies between animal and human studies?
Concomitant improvements in both insulin levels and body fat depots are often reported in rodents fed resistant starches. This is in contrast to studies in healthy humans or patients with metabolic syndrome in which resistant starches feeding improves insulin sensitivity without having a major impact on fat mass. Several factors likely contribute to this discrepancy, one of which is the gut microbiota. Human and rodent microbiomes are strikingly dissimilar and may vary widely in their response to resistant starches. Another explanation could be the vastly different resistant starch doses fed during the animal studies, which often range from 30 to 55% of the diet. Unfortunately, these doses are likely not realistic for human diets. Feeding higher doses of resistant starches during animal studies may also explain why increased SCFA production is frequently reported in rodents but not humans, as SCFA production is a dose-dependent phenomenon. SCFA, working to stimulate PYY and GLP-1 secretion, could potentially reduce fat mass, whereas other mechanisms (independent of SCFA and GLP-1) may improve insulin sensitivity. This working model would explain why resistant starch feeding does not have a profound impact on fat mass in humans but still enhances insulin sensitivity.
What accounts for the variation and inconsistency among experiments?
Beyond the discrepancies described among the various animal models and human populations, inconsistencies have even been reported within the same experimental design. What causes this variation is not understood. However, interactions between resistant starches and the gut microbiome could potentially contribute, as microbiota composition differs widely among animal facilities, is highly individualized in humans (especially in Westernized societies) [38] , and is influenced by dietary regimen. If resistant starches do indeed impact host physiology via effects on the microbiome, one would assume these responses to differ among vivaria or people. The ability of resistant starch type 2 to reduce fat mass in mice has not been detected consistently across experiments and is associated with whether or not a particular cohort of mice fermented the resistant starches [5 & ]. These observations collectively point to functional differences in the microbiome. In addition, human microbiomes also vary in their ability to utilize resistant starches. For example, Ruminoccocus bromii has been shown to be a keystone bacterial species required to begin the resistant starch type 3 degradation process, and the starch remains untouched in persons who do not harbor this species [39] . There have been attempts to determine microbiome responsiveness to resistant starch type 3 based on characteristics of an individual's fecal microbiome composition, especially at baseline [22 & ]. This concept is still in its infancy, but if the microbiota, indeed, confers the metabolic effects of resistant starches, variation in the functional response of individuals' gut microbes will likely impact the outcomes of clinical trials. Considering these characteristics will introduce the microbiome into the realm of personalized nutrition.
What is the functional relevance of the chemical differences among resistant starch types?
We often speak of resistant starches as a whole. However, resistant starches encompass a wide variety of structures, and this heterogeneity could also explain, at least in part, some apparent discrepancies among studies. Several pathways are likely involved in mediating the metabolic benefits associated with consuming resistant starches. It is, therefore, quite possible that the relative contribution of each of these pathways will vary from one structure to another. Due to their inherent and distinct physicochemical properties, specific types of resistant starches or even specific structures within a type may favor the growth of different gut microorganisms, which relates to disparities in how various resistant starches shape the human microbiome [4 & ,18,34,40] . Thus, systematic comparisons of different types of resistant starches regarding their unique ability to improve metabolic alterations are warranted.
CONCLUSION
The metabolic benefits of resistant starches for humans have been well established using gold standard techniques such as the euglycemic-hyperinsulinemic clamp. However, the mechanisms underpinning these effects remain to be elucidated. Progress in obtaining such an understanding requires a combination of clinical trials and experiments in animal models. Specifically, mechanisms must first be investigated using animal models -this information should then inform and be corroborated by clinical trials in which key biomarkers are assessed. In this framework, collecting samples from patients consuming resistant starches to investigate gut microbiota composition and function, bile acid profiles, and SCFA production becomes essential. Such research will ultimately provide the mechanistic insight needed to better design dietary strategies for specific human populations that, when combined with microbiome assessment, exemplify the concept of personalized nutrition. 
